312 related articles for article (PubMed ID: 37313403)
1. Cost-effectiveness analysis of toripalimab plus chemotherapy versus chemotherapy alone for advanced non-small cell lung cancer in China.
Zhang M; Xu K; Lin Y; Zhou C; Bao Y; Zhang L; Li X
Front Immunol; 2023; 14():1169752. PubMed ID: 37313403
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with Treatment-Naive Advanced Non-Small Cell Lung Cancer.
Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
[TBL] [Abstract][Full Text] [Related]
3. Toripalimab plus chemotherapy vs. chemotherapy in patients with advanced non-small-cell lung cancer: A cost-effectiveness analysis.
Huo G; Liu W; Kang S; Chen P
Front Pharmacol; 2023; 14():1131219. PubMed ID: 36865925
[No Abstract] [Full Text] [Related]
4. Economic evaluation of toripalimab combined with chemotherapy in the treatment of non-small cell lung cancer.
Wang H; Long Y; Xu Y; Liao L; Zhou Y
Front Public Health; 2023; 11():1137255. PubMed ID: 37033059
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness analysis of first-line toripalimab plus chemotherapy in advanced nonsquamous non-small cell lung cancer in China.
Zheng Z; Zhu G; Cao X; Cai H; Zhu H
Expert Rev Clin Pharmacol; 2023 Mar; 16(3):267-273. PubMed ID: 36877089
[TBL] [Abstract][Full Text] [Related]
6. Toripalimab plus chemotherapy in American patients with recurrent or metastatic nasopharyngeal carcinoma: A cost-effectiveness analysis.
Lian D; Gan Y; Xiao D; Xuan D; Chen Y; Yang Y
Cancer Med; 2024 May; 13(10):e7243. PubMed ID: 38752448
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of toripalimab plus chemotherapy for advanced esophageal squamous cell carcinoma.
Xu K; Wu H; Zhou C; Bao Y; Yu M; Zhang L; Li X
Int J Clin Pharm; 2023 Jun; 45(3):641-649. PubMed ID: 36800145
[TBL] [Abstract][Full Text] [Related]
8. Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: A cost-effectiveness analysis.
Liang X; Chen X; Li H; Liu X; Li Y
Front Public Health; 2023; 11():1054405. PubMed ID: 36923040
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of toripalimab plus chemotherapy for patients with advanced esophageal squamous cell carcinoma in China.
Kang S; Wang X; Pan Z; Liu H
Expert Rev Pharmacoecon Outcomes Res; 2024 Feb; 24(2):285-292. PubMed ID: 37855081
[TBL] [Abstract][Full Text] [Related]
10. Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer.
Liang X; Chen X; Li H; Li Y
Front Public Health; 2023; 11():1009920. PubMed ID: 36794070
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of camrelizumab plus chemotherapy as first-line treatment for advanced squamous NSCLC in China.
Shao T; Ren Y; Zhao M; Tang W
Front Public Health; 2022; 10():912921. PubMed ID: 36045725
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of second-line atezolizumab in Canada for advanced non-small cell lung cancer (NSCLC).
Ondhia U; Conter HJ; Owen S; Zhou A; Nam J; Singh S; Abdulla A; Chu P; Felizzi F; Paracha N; Sangha R
J Med Econ; 2019 Jul; 22(7):625-637. PubMed ID: 30836031
[No Abstract] [Full Text] [Related]
14. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
15. First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China.
Yang Z; Zhu Y; Xiang G; Hua T; Ni J; Zhao J; Lu Y; Wu Y; Chang F
Expert Rev Pharmacoecon Outcomes Res; 2021 Oct; 21(5):1061-1067. PubMed ID: 33682554
[No Abstract] [Full Text] [Related]
16. Cost-effectiveness analysis of toripalimab plus chemotherapy as the first-line treatment in patients with advanced non-small cell lung cancer (NSCLC) without EGFR or ALK driver mutations from the Chinese perspective.
Zhou K; Shu P; Zheng H; Li Q
Front Pharmacol; 2023; 14():1133085. PubMed ID: 37266153
[No Abstract] [Full Text] [Related]
17. Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC.
Chen P; Wang X; Zhu S; Li H; Rui M; Wang Y; Sun H; Ma A
Front Public Health; 2022; 10():956792. PubMed ID: 36016894
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China.
Liu S; Jiang N; Dou L; Li S
Front Immunol; 2023; 14():1172242. PubMed ID: 37215110
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adding rh-endostatin to first-line chemotherapy in patients with advanced non-small-cell lung cancer in China.
Wu B; Chen H; Shen J; Ye M
Clin Ther; 2011 Oct; 33(10):1446-55. PubMed ID: 21992806
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of atezolizumab plus chemotherapy as first-line treatment for patients with advanced nonsquamous non-small-cell lung cancer in China.
Shang F; Zhang B; Kang S
Expert Rev Pharmacoecon Outcomes Res; 2023 Mar; 23(3):337-343. PubMed ID: 36655382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
